These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Current status of CETP inhibitors in the treatment of hyperlipidemia: an update. Ghosh RK; Ghosh SM Curr Clin Pharmacol; 2012 May; 7(2):102-10. PubMed ID: 22432840 [TBL] [Abstract][Full Text] [Related]
11. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein. Oram JF; Heinecke JW Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780 [No Abstract] [Full Text] [Related]
13. HDL cholesterol: all hope is not lost after the torcetrapib setback--emerging therapeutic strategies on the horizon. Verma N; Figueredo VM Am J Ther; 2014; 21(3):222-32. PubMed ID: 22967983 [TBL] [Abstract][Full Text] [Related]
14. Effect of cholesteryl ester transfer protein inhibitor on vitamin E transport should be studied. Masterjohn C Am Heart J; 2009 Jul; 158(1):e11; author reply e13. PubMed ID: 19540377 [No Abstract] [Full Text] [Related]
15. HDL cholesterol and atherosclerosis. Mazzone T Lancet; 2007 Jul; 370(9582):107-108. PubMed ID: 17630020 [No Abstract] [Full Text] [Related]
16. Novel cholesteryl ester transfer protein inhibitors: promising therapy for dyslipidemia? Devaraj S; Jialal I Metab Syndr Relat Disord; 2011 Jun; 9(3):163-5. PubMed ID: 21557663 [No Abstract] [Full Text] [Related]
17. Anacetrapib: a potential new therapy for dyslipidemia. Robinson LB; Frishman WH Cardiol Rev; 2014; 22(5):253-61. PubMed ID: 24618931 [TBL] [Abstract][Full Text] [Related]
18. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase. Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406 [TBL] [Abstract][Full Text] [Related]
19. Anacetrapib as a potential cardioprotective strategy. Di Bartolo BA; Nicholls SJ Drug Des Devel Ther; 2017; 11():3497-3502. PubMed ID: 29263647 [TBL] [Abstract][Full Text] [Related]
20. The failure of torcetrapib: what have we learned? Joy TR; Hegele RA Br J Pharmacol; 2008 Aug; 154(7):1379-81. PubMed ID: 18536741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]